CervoMed Inc. closed its previously announced registered direct offering priced at-the-market under Nasdaq rules on June 22, 2026. The company sold 2,500,000 shares of its common stock at a purchase price of $4.00 per share, resulting in gross proceeds of $10 million before deducting placement agent fees and other offering expenses. CervoMed intends to use the net proceeds from the offering for working capital and general corporate purposes.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282494), which was declared effective by the Securities and Exchange Commission (SEC) on October 10, 2024. The offering was made only by means of a prospectus supplement forming part of the effective registration statement.

CervoMed is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain. The company recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nonfluent variant primary progressive aphasia, with interim biomarker data anticipated in the early fourth quarter of 2026.

Offering Details

CervoMed Inc., a clinical-stage biotechnology company, has secured a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering its drug candidate neflamapimod. The patent protects the use of neflamapimod for treating dementia with Lewy bodies (DLB) in patients without substantial Alzheimer's disease-like tau pathology, a condition referred to as "pure DLB". This intellectual property protection is expected to extend into 2042, with potential for longer coverage through patent term extensions.

The patent specifically covers the treatment of DLB characterized by the absence of substantial tau pathology, which can be identified via plasma levels of pTau or brain imaging. This protection supports CervoMed's strategy to target patients specifically suffering from pure DLB. Currently, there are no approved treatments for DLB in the United States or the European Union, highlighting the significance of this development for the company's pipeline.

Patent Details

The newly allowed patent provides CervoMed with a strategic advantage in the neurodegenerative disease space. Below are the key details regarding the patent and the drug candidate:

Strategic Context

By securing this patent, CervoMed reinforces its focus on age-related brain disorders. The allowance notice marks a progression in the company's efforts to bring a therapeutic option to a market that currently lacks approved treatments for DLB. The exclusivity granted by the patent is critical for the commercial viability of neflamapimod should it receive regulatory approval.